Table 1.
Baseline characteristics of all patients intended for adjuvant therapy versus observation
| All patients (N=98) | Observation cohort 1 (n=49) | Adjuvant intention cohort 2 (n=49) | P value | |
| Age | 0.027 | |||
| Median | 63 | 69 | 59 | |
| IQR | 54–73 | 54–76 | 53–70 | |
| Sex | 0.306 | |||
| Male | 57 (58) | 31 (63) | 23 (47) | |
| Female | 41 (42) | 18 (37) | 26 (53) | |
| Site primary | 0.055 | |||
| Extremities | 50 (51) | 31 (63) | 19 (39) | |
| Trunk | 41 (42) | 15 (31) | 26 (53) | |
| Head and neck | 2 (2) | 0 | 2 (4) | |
| Acral | 1 (1) | 0 | 1 (2) | |
| Mucosal | 2 (2) | 2 (4) | 0 | |
| MUP | 2 (2) | 1 (2) | 1 (2) | |
| Breslow thickness | 0.369 | |||
| ≤1.0 mm | 7 (7) | 2 (4) | 5 (10) | |
| 1.01–2.0 | 25 (26) | 13 (27) | 12 (25) | |
| 2.01–4.0 | 37 (38) | 21 (43) | 16 (33) | |
| >4.0 | 21 (21) | 8 (16) | 13 (27) | |
| Unknown | 8 (8) | 5 (10) | 3 (6) | |
| Ulceration | 0.067 | |||
| No | 53 (54) | 21 (43) | 32 (65) | |
| Yes | 29 (30) | 17 (35) | 12 (25) | |
| Unknown | 16 (16) | 11 (22) | 5 (10) | |
| Stage (AJCC 8th edition) | 0.718 | |||
| IIIB | 14 (14) | 5 (10) | 9 (18) | |
| IIIC | 78 (80) | 41 (84) | 37 (76) | |
| IIID | 4 (4) | 2 (4) | 2 (4) | |
| Unknown | 2 (2) | 1 (2) | 1 (2) | |
| Mutation status | 0.031 | |||
| BRAF | 59 (60) | 24 (49) | 35 (71) | |
| NRAS | 24 (25) | 12 (25) | 12 (25) | |
| cKIT | 1 (1) | 1 (2) | 0 | |
| No driver mutations | 10 (10) | 8 (16) | 2 (4) | |
| Unknown | 4 (4) | 4 (8) | 0 | |
| Type of surgery | 0.002 | |||
| LND | 54 (55) | 18 (37) | 36 (74) | |
| ITM | 20 (20) | 13 (27) | 7 (14) | |
| LND+ITM | 10 (10) | 6 (12) | 4 (8) | |
| ILP±LND | 14 (14) | 12 (25) | 2 (4) | |
| S100b | 0.905 | |||
| ≤ULN | 81 (83) | 39 (80) | 42 (86) | |
| >ULN | 12 (12) | 6 (12) | 6 (12) | |
| Unknown | 5 (5) | 4 (8) | 1 (2) | |
| LDH | 0.009 | |||
| ≤ULN | 85 (87) | 38 (78) | 47 (96) | |
| >ULN | 6 (6) | 6 (12) | 0 | |
| Unknown | 7 (7) | 5 (10) | 2 (4) |
Reported as number (%), percentages may not total 100 due to rounding.
P<0.05 is statistically significant and set in bold.
ILP, isolated limb perfusion; IQR, Interquartile Range; ITM, in-transit metastasis; LND, lymph node dissection; MUP, melanoma of unknown primary; ULN, upper limit of normal.